ClinicalTrials.gg
RecruitingNCT05101382ALFAOMEGA-RUpdated Aug 24, 2025

A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)

An observational study in Colorectal Cancer, sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Colorectal Neoplasms with a site in Italy — 103 open to participants now, 143 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.

Planned enrollment
32nd of 96
500 · median 258
Started
2020
with 28 others
Observational
96 of 429
33 open now
Primary completion
2026-06
later than 40 of 142 live
Registered
296th of 429
by date

Among the 429 studies in Colorectal Neoplasms with a site in Italy, this one is the 32nd largest by planned enrollment of the 96 observational ones that give a count, is one of 29 that started in 2020, is one of 96 observational ones, reaches primary completion later than 40 of the 142 other live ones, and was the 296th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

103 of the 429 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Colorectal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

ALFAOMEGA-RETRÒ will be exploited to retrospectively collect clinical and imaging data and archival samples to be used for validation and correlative studies on markers discovered by cutting-edge translational projects within the AIRC5x1000 program "Insights into the evolving heterogeneity of colorectal cancer (CRC): from mechanism to therapies" (an ongoing multi-institutional research program).

Read the detailed description

ALFAOMEGA-RETRÒ, the retrospective "mirror" protocol of ALFAOMEGA (protocol n. IFOM-CPO003/2018/PO002), has been designed to build a retrospective collection of clinically annotated data and biological samples retrieved from colorectal cancer patients (CRC).

The repository will feed experimental precision research aimed at i) defining a new taxonomy of CRC based on evolutionary patterns (retrospectively assessed on patient's samples), ii) developing and evaluating innovative biomarker-specific therapeutic strategies derived from or together with ALFAOMEGA.

The following data and biological samples will be collected:

  • Clinical Data (Demographics, Medical History, Cancer Diagnosis \& History, Treatment Assessment,).
  • Imaging Data (CT-Scans, MRI, PET...).
  • Formalin-Fixed Paraffin-Embedded (FFPE) tissue (either from surgical resections or diagnostic biopsies).
  • Frozen biological samples (blood, plasma, PBMC, stools, buccal swabs, urines, etc.).
03

Conditions studied

  • Colorectal Cancer

Keywords

  • colorectal cancer
  • CRC
  • Gastrointestinal disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

at least 500 colorectal cancer patients at any stage who cannot be reached for an informed consent

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed diagnosis of colorectal cancer (any stage).
  • Age >18 years at the time of diagnosis.
  • Availability of clinically-annotated radio-imaging data and/or diagnostic Formalin-Fixed Paraffin Embedded (FFPE) blocks (surgical resections and/or tumor ), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.
  • Verification that the patient could not be reached for in accordance with applicable national regulations.

Exclusion criteria

Exclusion Criteria:

  • if inclusion criteria are not met
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort of CRC patients

    Stage-mixed cohort of at least 500 CRC patients that cannot be reached for informed consent (death or lost-to-follow-up)

    Other: Observation

Interventions

  • OtherObservation

    Retrospective Observation of standard clinical practice

06

What researchers measure

Primary outcomes

  1. Number of retrospectively recruited CRC cases

    Number of retrospectively recruited CRC cases with complete matched clinical data, radio-imaging data and FFPE or frozen biological samples.

    Time frame: 6 months

Other outcomes

  1. Number of new prognostic and predictive markers

    Number of identified/validated new independent prognostic and predictive biomarkers

    Time frame: 6 months

  2. Biomarkers correlation with PFS

    Correlation of new prognostic and predictive biomarkers with progression-free survival (PFS).

    Time frame: 6 months

  3. Biomarkers correlation with OS

    Correlation of new prognostic and predictive biomarkers with overall survival (OS).

    Time frame: 6 months

07

Study locations

12 of 13 sites recruiting
  • Ospedale Policlinico San Martino
    Genova, GE 16132, Italy
    Recruiting
    • Stefania Sciallero, MD · Contact
    • Stefania Sciallero, MD · Principal investigator
  • Fondazione IRCCS, Istituto Nazionale dei Tumori
    Milan, MI 20133, Italy
    Recruiting
    • Filippo Pietrantonio, MD · Contact
    • Filippo Pietrantonio, MD · Principal investigator
  • Niguarda Cancer Center - ASST Grande Ospedale Metropolitano Niguarda
    Milan, MI 20162, Italy
    Recruiting
    • Emanuela Bonoldi, MD · Contact
    • Emanuela Bonoldi, MD · Principal investigator
  • IRCCS Istituto Clinico Humanitas
    Milan, MI, Italy
    Recruiting
    • Alberto Puccini, MD · Principal investigator
  • Istituto Oncologico Veneto (IOV)
    Padua, PD 35128, Italy
    Recruiting
    • Sara Lonardi, MD · Contact
    • Sara Lonardi, MD · Principal investigator
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Pisa 56126, Italy
    Recruiting
    • Chiara Cremolini, MD · Principal investigator
  • Istituto di Candiolo - IRCCS
    Candiolo, TO 10060, Italy
    Recruiting
    • Caterina Marchiò, MD · Contact
    • Caterina Marchiò, MD · Principal investigator
  • Azienda Ospedaliero Universitaria San Luigi Gonzaga
    Orbassano, TO 10043, Italy
    Recruiting
    • Maurizio Degiuli, MD · Contact
    • Maurizio Degiuli, MD · Principal investigator
  • Azienda Ospedaliera Ordine Mauriziano
    Torino, TO 10128, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Institut Català D'Oncologia (ICO)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Cristina Santos · Principal investigator
  • Hospital del Mar - Parc de Salut Mar
    Barcelona, 08003, Spain
    Recruiting
    • Clara Montagut, MD · Contact
    • Clara Montagut, MD · Principal investigator
  • Vall d'Hebron Institute of Oncology (VHIO)
    Barcelona, 08035, Spain
    Recruiting
    • Elena Élez, MD · Contact
    • Elena Élez, MD · Principal investigator
  • INCLIVA - Instituto de Investigatión Sanitaria
    Valencia, 46010, Spain
    Recruiting
    • Andres Cervantes, MD · Contact
    • Andres Cervantes, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Jun 2026, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Nov 1, 2021
StartActual
Oct 28, 2020
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05101382
Lead sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Oct 28, 2020
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 24, 2025

Study contacts

Luca Lazzari, PhD
Contact
clinical.trials@ifom.eu
+3902574303799
Smeralda Rapisarda
Contact
clinical.trials@ifom.eu
+3902574303236
Silvia Marsoni, MD
study director · IFOM ETS - The AIRC Institute of Molecular Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion